Botulinum toxin type A (BTXA) is effective in the treatment of keloids and other hypertrophic scarring, but the mechanism has not always been clear. The hypothesis behind the early use of BTXA to treat these conditions was that BTXA may inhibit the growth of fibroblasts. A recent study further explored that mechanism by examining the …
Keloids are thought to be rare in children as they are most commonly seen in the second decade of life. This is thought to be due to the pathogenesis of the disorder brought on by hormonal changes in people in young adult hood. A recent study examined the demographic characteristics of non-burn-related keloids in children …